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correlation between the presence of SV40 viral sequences and the path-
ological type of the tumor since 13 out of the 20 SV40 positive cases 
(65%) were of the sarcomatoid/mixed variants compared to 7 (35%) of 
the epithelioid variant (p.= 0.03). Similarly, there was a statistically sig-
niﬁcant correlation between the presence of SV40 viral sequences and 
a positive history of asbestos exposure (p. = 0.03). Univariate analysis 
showed a signiﬁcant correlation between OS and stage (p= 0.03), 
performance status (p=0.04), p53 overexpression (p=0.05), asbestos 
exposure (p=0.002) and SV40 (p=0.001). Multivariate analysis showed 
that when SV40 and asbestos exposure were considered together, only 
combined positivity of both is an independent prognostic factor affect-
ing the OS (p = 0.001).
Conclusion: SV40 and asbestos exposure are common in Egyptian 
MPM denoting a possible etiological role and a synergistic effect for 
both agents. Our results prove that combined positivity for SV40 and 
asbestos exposure is an independent prognostic factor in MPM having 
a detrimental effect on OS
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Clinical features of endotracheal / endobronchial metastases: 
analysis of 55 cases
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Objective: To discuss the clinical presentation, diagnosis and treatment 
of endotracheal/endobrocnchial metastases (EEM). 
Methods: Retrospective and follow-up analyses were conducted of 55 
cases of bronchoscopically conﬁrmed EEM. Clinical staging, loca-
tion in the tracheobronchial tree, the number of lesions, treatment and 
prognosis were analyzed. 
Results: The most common neoplasms associated with EEM were 
esophageal carcinoma (50.9%) and gastric cancer (9.1%). Most EEM 
patients presented with cough, hemoptysis, dyspnea, chest pain and 
fever. Abnormal changes on chest X-ray were found in 83.6% cases, 
and CT imageological changes were found in all patients. There were 
29/66 lesions in the trachea, and 37/66 in the bronchus, including 18 in 
the right bronchus and 19 in the left bronchus. Type I EEM accounted 
for 22/66 cases; Type II, 20/66 cases; Type III, 10/66 cases, and Type 
IV, 14/66 cases. The median survival time was 8.1 months. There was 
signiﬁcant difference in survival time between Type IV EEM and the 
other three types.
Conclusion: EEM may occur in the trachea or in the bronchus. 
Flexible bronchoscopy is a valuable tool for the diagnosis of EEM. 
Although there are cases of long survival, the prognosis of EEM is 
generally poor.
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Background: Malignant pleural mesothelioma (MPM) is a rare and 
aggressive cancer. Asbestos ﬁbers exert their well-recognized causative 
effect on MPM through the direct or indirect generation of reactive 
oxygen and nitrogen species. Many genes that encode for xenobiotic 
and oxidative metabolism enzymes are polymorphic, resulting in pos-
sible individual differences in cancer risk. Two previous studies related 
the risk of MPM with few genetic polymorphisms of xenobiotic and 
oxidative metabolism enzymes, as assessed by PCR techniques, gener-
ating the hypothesis that genetic variation may have a role in individual 
susceptibility to MPM. An association study performed in a case-con-
trol setting including 90 MPM patients and 395 referent subjects is 
described. Thirtyﬁve single nucleotide polymorphisms (SNP) in 10 
genes of phase I and 27 SNPs in 8 genes of phase II of the xenobiotic 
metabolism were explored in relation to the risk of MPM. 
Methods: The polymorphisms were analyzed all at once for a given 
sample by a micro-array technique based on the arrayed-primer exten-
sion (APEX) principle. 
Results: After adjusting for multiple comparisons according to the 
Wacholder method, a general lack of statistically signiﬁcant associa-
tion was evident, with the exceptions of CYP1B1 and NAT1. The 
homozygotes carrying the variant R48G within CYP1B1 were found 
at about four-fold increased risk of MPM respect to homozygotes wild 
type (OR=4.22, 95% CI 1.68-10.61, p=0.002). In addition, the ORs 
calculated for the diplotypes showed that there are haplotypes as-
sociated with the risk of MPM. The slow and intermediate acetylator 
phenotypes for NAT1 posed an increased risk of MPM respect to the 
fast acetylator genotype (OR=4.46, 95%CI 1.07-18.63 and OR=2.35, 
95% CI 1.03-5.4, respectively). 
Conclusions: The present study reinforces the hypothesis that the 
acetylator-phenotype plays a role in relation to the etiology of MPM 
and suggests CYP1B1 as a novel risk factor for MPM.
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The dosimetric effects of changes in thoracic cavity fluid levels 
during adjuvant hemithoracic intensity modulated radiotherapy 
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Background: Malignant pleural mesotheliomas are rare tumours 
involving the pleural lining of the lung, often associated with asbes-
tosis. We offer aggressive tri-modality treatment in carefully selected 
patients, consisting of neoadjuvant chemotherapy (cisplatin and peme-
trexed) followed by extrapleural pneumonectomy followed by adjuvant 
hemithoracic intensity modulated radiotherapy (IMRT). Usually the 
thoracic cavity (TC) becomes completely ﬂuid ﬁlled after surgery and 
is stable throughout treatment. However, in some patients, the TC is 
partially ﬁlled at the beginning and the ﬂuid levels may change during 
radiation. Clearly, increasing the density of the TC contents will tend to 
attenuate the dose delivered (and vice versa). However, the magnitude 
of these effects are not well understood. The aim of this study is to 
investigate the clinical signiﬁcance of these dosimetric effects.
Methods: The patient was planned using the Inverse Planning module 
of the Pinnacle treatment planning system (version 7.6c). Appropri-
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ate dose constraints are applied to the clinical target volume (CTV), 
planning target volume (PTV), contralateral lung, heart, spinal cord, 
esophagus, liver and kidneys. Beam geometry consisted of 8 non-
overlapping coplanar beams (mixed 6/10 MV photons). The PTV was 
prescribed 50 Gy in 25 daily fractions over 5 weeks. Bolus was applied 
over the scar to ensure adequate skin dose. The plan was optimized in 
the partially ﬁlled TC case. A density override was applied to the TC to 
simulate the completely ﬁlled TC (1 g/cm3) and completely empty (0 
g/cm3) cases, assuming identically treated plans (same monitor units). 
The doses to the regions of interest were compared.
Results: Comparing the empty, partially ﬁlled and full TC cases re-
spectively, we ﬁnd: mean CTV dose 53.4. 50.7 and 49.6 Gy, mean PTV 
dose 53.1, 50.4 and 49.4 Gy; mean contralateral lung dose 8.8, 8.4 and 
8.3 Gy; mean heart dose 32.0, 28.4 and 28.5 Gy; max spinal canal dose 
50.0, 48.9 and 47.3 Gy; max esophagus dose 56.5, 54.0 and 54.6 Gy; 
mean liver dose 20.6, 19.8 and 19.9 Gy; mean ipsilateral kidney dose 
6.9, 7.1 and 7.1 Gy. 
Conclusions: Dosimetric differences between partially ﬁlled and full 
TC are modest, usually within 1 Gy, and, thus, not likely to be of major 
clinically relevance. In general, the empty and full TC had slightly 
warmer and cooler doses, respectively, compared to the partially ﬁlled 
TC case but this was not universally true for all organs at risk. The 
empty TC had the largest dosimetric differences, sometimes exceeding 
2 Gy, compared to the other cases and, thus, may warrant further clini-
cal study and caution.
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Background: Bronchoscopic intervention as initial treatment for rela-
tively benign intraluminal lesions has been shown to potentially spare 
lung parenchyma without compromising long-term outcome, relative to 
surgical resection. 
Aim: To evaluate outcome of bronchoscopic treatment for patients 
with lipoma, neuroﬁbroma, hamartoma, chondroma, hemangioma, 
papilloma, granular cell myoblastoma and low-grade mucoepidermoid 
carcinoma involving the tracheobronchial tree.
Methods: Retrospective review of pathology and bronchoscopy data-
bases between 1992 and 2006 was performed to identify patients with 
relatively benign airway tumors referred to our hospital for broncho-
scopic intervention. Initial clinical work-up included high resolution 
computed tomography (HRCT) for tumor location and invasion. All 
patients underwent rigid bronchoscopy for diagnostic and therapeutic 
indications. Endobronchial electrosurgery followed by mechanical 
debulking of the intraluminal tumor. Restaging with bronchoscopy and 
HRCT were carried out 4-6 weeks after bronchoscopic intervention. 
Patients with extraluminal or residual tumor and distal lung atelectasis 
were advised for surgery.
Results: We identiﬁed 44 patients, 15 females with median age 54 
yrs (range 18 -81), who were initially treated bronchoscopically:16 
(chondro)hamartomas, 6 mucoepidermoid carcinomas, 6 granular cell 
myoblastomas, 4 lipomas, 3 papillomas, 3 adenomas, 2 neuroﬁbromas, 
1 hemangioma, 1 lymfangioma, 1 leiomyoma and 1 paraganglioma. 
Thirty-ﬁve patients (80%) were curatively treated by bronchoscopic 
treatment alone (80%). In the remaining nine patients, radical resection 
was performed. Median follow-up until March 2007 was 38 months 
(range: 4-152) and there were no complications observed in patients 
who underwent bronchoscopic treatment. There has been one patient 
with a recurrence of a hamartoma 20 weeks after bronchoscopic inter-
vention; a segmentectomy was performed. 
Conclusion: Bronchoscopic treatment of relatively benign intraluminal 
tumors in the treacheobronchial tree can be initiated and is a safe alter-
native for surgery, which can be performed if bronchoscopic treatment 
initially failed. 
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Background: Evaluate efﬁcacy of diagnostic measures and surgery for 
malignant pleural mesothelioma (MPM) and analyse results of treat-
ment. 
Matherial and Methods: Form 1992-2005 yy. 138 patients (pts) 
underwent treatment for morphologicaly proved malignant pleural 
mesothelioma in Department of Thoracic Surgery and Oncology, 
Institute Oncology Vilnius University. 113 (81.9%) pts were operated, 
25 (18.1%) pts underwent conservative treatment (radiation/chemo-
therapy). Before operation noninvasive diagnostic procedures were 
used: X-ray ﬁlms 138 (100%) pts, X-ray ﬁlms and chest CT 56 (40.5%) 
pts, chest CT 62 (44.9%) pts, chest CT/MRI 10 (7.2%) pts and chest 
ultrasound 10 (7.2%) pts. Invasive diagnostic procedures: VATS - 45 
(32.6%) pts, pleural biopsy 82 (59.4%) pts, diagnostic (mini) thoracot-
omy 11 (7.9%) pts. Stage of the disease: I st. - 17 (12.3%) pts, II st.- 35 
(25.3%) pts, III st. - 60 (43.4%) pts and stage IV - 26 (18.8%) pts. 53 
pts after surgery were treated using radiation/chemotherapy. 
Results: Operation for MPM: pleuropulmonectomy - 68 (60.1%) pts, 
extented pleuropulmonectomy with pericardium and diafragm resection 
- 12 (10.6%), parietal pleurectomy - 12 (10.6%), partial pleurectomy 
with pericardial resection - 11 (9.7%) pts, debulking - 10 (8.8%) pts. 
Morphology found: epitheliod - 48 (35.7%) pts, sarcomatosus - 53 
(38.4%) pts and biphasic - 37 (26.8%) pts. Postoperative complications: 
bronchial ﬁstulas - 6 (5.3%) pts, chylothorax - 7 (6.1%) pts, hemotho-
rax - 11 (9.7%) pts and injury of simpatic ganglion - 2 (1.7%) pts. 4 
(3.5%) pts dead after surgery. Median survival after surgery was 12,0±2 
mo., after conservative treatment - 6,0±2 mo. Reccurence of the disease 
in surgical group ranges from 9.7-17.6% of pts, in conservative group 
no one pts lived three years. 
Conclusions: 1. Surgery for MPM is conﬁdent, radical and sufﬁcient 
method of treatment. 2. Nonradical resections and postoperative 
chemoradiation prolongs disease free survival and overall survival. 3. 
Postoperative complications was in 26 (23% ) pts, 4 (3.5%) pts dead. 4. 
Median survival after surgery was 12,0±2 mo., after conservative treat-
ment - 6,0±2 mo. Reccurence of the disease in surgical group ranges 
from 9.7-17.6% of pts, in concervative group 93%. 
